Adding Retifanlimab To Chemotherapy Provides OS Benefit over Chemotherapy In First-Line Treatment of Patients with Advanced Squamous Anal Cancer By Ogkologos - May 18, 2026 138 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival analysis in the POD1UM-303/InterAACT-2 study Source RELATED ARTICLESMORE FROM AUTHOR Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer Metastatic Breast Cancer: ESMO Living Guideline EMA Recommends Extension of Indications for Datopotamab Deruxtecan MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Germanium (68Ge) chloride /... June 28, 2024 KRASG12 Mutations Are Biomarkers for Reduced Overall Survival Benefit of Treatment... March 14, 2023 How Can Occupational Therapy Assist with Chemotherapy-induced Peripheral Neuropathy? April 27, 2021 From Practice-Changing Data to Future Innovation, Patient Outcomes to Doctors’ Wellbeing,... September 13, 2024 Load more HOT NEWS Picking out the sound of tumours Opinion: ‘Let’s not be short-sighted – the UK’s medical research charities... FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory... NGS Is Effective in Identifying Actionable Genetic Alterations for Investigational Targeted...
